SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Ifabotuzumab

Cat. No.:	HY-P99655
CAS No.:	2147698-66-4
Target:	Ephrin Receptor; Apoptosis
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K_D=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) $CCR10^+$ cells and improves pulmonary fibrosis[1][2].

In Vivo

Ifabotuzumab (5 mg/kg; i.p.; twice weekly for 5 weeks) improve pulmonary fibrosis in human mouse model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Humanized NSG mice with lung fibrosis[1]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; twice weekly for 5 weeks
Result:	Significantly reduced hydroxyproline to levels and IL-6 transcript levels. Significantly reduced the total number of $CCR10^+EphA3^+$, as well as Lin^-CCR10^+ cells.

REFERENCES

[1]. Hohmann MS, et al. Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF. JCI Insight. 2021 Jun 8;6(11):e141061.

[2]. Swords R T,et al. KB004, a novel non-fucosylated humaneered® antibody, targeting EphA3, is active and well tolerated in a phase I/II study of advanced hematologic malignancies[J]. Blood, 2014, 124(21): 3756.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA